RT @Maria_Var_Cal: Un año más #CarrerHUCA 🏃🏻‍♀️🏃🏻‍♂️ @HUCA_Asturias

Un año más #CarrerHUCA 🏃🏻‍♀️🏃🏻‍♂️ @HUCA_Asturias

Two months to go! A very promising event with international KOLs to debate all the information released in the last 12 months. Program at docs.academia.cat/mailing/16… Registration at inscripcions.academia.cat/fo… @hospitalclinic @idibaps @AEEHLiver @ContraCancerEs @ILCAnews

RT @inesmarsal: Asturias es Covadonga, sus montañas, el Cantábrico, sus pueblos, su gente y esa forma de sentir que solo quien es de aquí e…

Lessons from the Surgical Session @ILCAnews

HUCA representation in the ILCA annual conference 2026 @ILCAnews @HUCA_Asturias #TrabajoEnEquipo

🟣Second-line practices in the era of immunotherapy in #HCC: The CHIEF cohort 🔓#OpenAccess at👉sciencedirect.com/science/ar… #HCC #HepatocellularCarcinoma #LiverTwitter #LiverHealth

🟣Scientific, regulatory, and practical considerations for bringing hepatocellular carcinoma biomarkers into clinical practice 🔓#OpenAccess at👉sciencedirect.com/science/ar… #HCC #HepatocellularCarcinoma #LiverTwitter #LiverHealth

Cocinando este verano: ¿Cuánta harina echo? La que admita ¿Cuánta agua echo? La que pida #RecetasDeFamilia

EMERALD-3: a global, randomised, open-label, sponsor-blinded, phase 3 study - The Lancet Oncology thelancet.com/journals/lanon…

🔴 BAVENO VIII – Portal Hypertension: What Changes Clinical Practice? 📌 Baveno VIII – Advancing Consensus in Portal Hypertension The Baveno VIII consensus, developed across 9 expert panels, achieved strong consensus on 272 statements/recommendations and proposes 153 research priorities. The central message continues the paradigm shift from simply preventing variceal bleeding to identifying clinically significant portal hypertension (CSPH) early and preventing first and further hepatic decompensation. 🔑 1. CSPH remains the pivotal therapeutic threshold CSPH = HVPG ≥10 mmHg, but invasive HVPG is no longer necessary for routine risk stratification in many compensated patients. 👉 Liver stiffness measurement (LSM), platelet count and increasingly spleen stiffness form the backbone of non-invasive assessment. Clinical pearl: Do not wait for varices to appear before thinking about portal-hypertension-directed treatment. 🔑 2. The “Rule of Five” remains clinically powerful Think progressively: LSM 5 → 10 → 15 → 20 → 25 kPa Increasing liver stiffness reflects progressively increasing probability of advanced liver disease, CSPH and clinical events. The well-validated Baveno framework remains: ✅ LSM ≤15 kPa + platelets ≥150 ×10⁹/L → CSPH can generally be ruled out. ✅ LSM ≥25 kPa → strongly supports CSPH in appropriate populations. But an important caveat is MASLD with obesity: an isolated LSM ≥25 kPa is less reliable for ruling in CSPH. Recent individual-patient meta-analysis showed that obesity materially reduces the reliability of this simple rule-in threshold. 🔑 3. The old 15–25 kPa “grey zone” is becoming smaller Patients falling between the classical rule-out and rule-in thresholds should not automatically undergo invasive testing. Additional tools such as: ➡️ platelet count ➡️ spleen stiffness measurement (SSM) ➡️ ANTICIPATE/ANTICIPATE-NASH probability models ➡️ selected biochemical algorithms can further refine CSPH probability. This is particularly relevant in steatotic liver disease and obesity, where a one-size-fits-all LSM threshold performs less well. 🔑 4. Carvedilol is not merely an “anti-variceal” drug This is one of the most important conceptual messages for physicians. In a compensated patient with CSPH, a non-selective β-blocker is used not only to prevent bleeding but to prevent hepatic decompensation, particularly ascites. Carvedilol remains particularly important because of its additional α1-blocking action and greater portal-pressure reduction. Thus the clinical thinking becomes: CSPH identified → ask whether NSBB/carvedilol is appropriate, rather than waiting for large varices. Baveno VII established this paradigm, and subsequent evidence has strengthened non-invasive identification of the patients most likely to benefit. 🔑 5. Endoscopy becomes more selective A major evolution of Baveno guidance is: Not every compensated patient with cirrhosis needs screening endoscopy solely to decide whether to start an NSBB. If CSPH is established and the patient is an appropriate candidate for an NSBB, treatment may be initiated on the basis of the portal-hypertension risk assessment. Endoscopy assumes greater importance when: ➡️ NSBBs are contraindicated/intolerable ➡️ the non-invasive assessment is uncertain ➡️ endoscopic therapy would alter management. This represents a move from “find varices and treat them” toward “identify portal hypertension and prevent decompensation.” 🔑 6. MASLD changes the portal-hypertension equation Baveno VIII gives increased importance to steatotic liver disease and its modifiers. ⚠️ Obesity can alter the diagnostic performance of VCTE. Therefore: LSM ≥25 kPa should not be interpreted mechanically in an obese MASLD patient. BMI, platelets and other NITs may need to be integrated. 📖Next .....journal-of-hepatology.eu/art…

It’s finally here‼️ 🎉 Baveno VIII has arrived — just in time for some good summer reading ☀️📖 Time to dive into the latest consensus on portal hypertension from @BavenoCoop Enjoy! 😉 🔗 journal-of-hepatology.eu/art…

En 1949 un médico inglés publicó 700 palabras en The Lancet que deberían leerse en voz alta cada vez que entra una generación nueva a un hospital. Casi nadie las lee. Los siete pecados de la medicina. 🧵

🔥off the press🔥 Systemic therapy for HCC: Doublets, triplets and beyond @JHepatology 👉comprehensive summary of systemic therapies in HCC 👇my author link authors.elsevier.com/sd/arti… @myESMO @EASLedu @ilca

📢 ¡ATENCIÓN! Acceso en abierto a la jornada final de la 13.ª edición del Máster de Formación Permanente en #Hepatología, de la #AEEH y @sepdigestiva. ✅Una oportunidad única para conocer las últimas novedades en #hepatología de la mano de expertos de la especialidad. 🗣️En esta jornada se actualizan temas relevantes y se abordan aspectos controvertidos de nuestra disciplina 🗓️10 de julio. Acceso en abierto vía Zoom. 🧑‍💻Enlace de registro ➡️ us06web.zoom.us/webinar/regi… 🔝¡No pierdas esta oportunidad de seguir avanzando en tu formación! #Hepatología #Máster #Formación #SaludHepática

Glad to contribute to this international consensus in @NatRevClinOncol rdcu.be/foH7g A joint effort by @EASLnews, @AASLDtweets, @ILCAnews, and @ASCO to advance clinical trial design and endpoints in HCC, helping generate more robust and clinically meaningful evidence👏

Hoy acaban su rotación HCC #LeireUrtasun del HUA ( Vitoria) y #Arantzazu Izaguirre @aranizagirre del HUD ( Donostia). #TrabajoEnEquipo

🚨 CRAFITY score may help guide 1L treatment selection in unresectable HCC @ResearchKarger 👉 In a retrospective international multicenter cohort of 994 patients, lenvatinib showed longer PFS than Ate/Bev in CRAFITY 2: 4.4 vs 2.3 months; HR 0.66, p=0.017. 👉 Benefit direction differed by CRAFITY score: Ate/Bev comparable or favored in CRAFITY 0–1, lenvatinib favored in CRAFITY 2 (interaction p=0.002). Ueno et al., Liver Cancer Atezolizumab Plus Bevacizumab Versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study DOI: doi.org/10.1159/000552808 @ILCAnews @myESMO @ASCO @EASLnews #HCC #CRAFITY #Lenvatinib #AteBev

⏬Download the Best of #EASLCongress Slide Decks on #EASLCampus! These editable Slide Decks bring together the top selected abstracts from the Congress in each topic track. 📚 🔗easlcampus.eu/Documents/best… @EASLNews @CornbergMarkus @JasmohanBajaj @hlcortezpinto @Alexfornergon @horstef @SilviaAffo #LiverX #BestOf

📅 29/05/2026 · 📍 Salón de Actos del HUCA El viernes despedimos a nuestros residentes del Área de Salud II. Gracias por vuestra dedicación y compromiso. 🎓💙